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ABSTRACT 
Rare sequence variants in “high-risk” disease genes often referred as Unclassified Variants 
(UVs) pose a serious challenge to genetic testing. However, UVs resulting in splicing 
alterations can be readily assessed by in vitro assays. Unfortunately, analytical and clinical 
interpretation of these assays is often challenging. Here we explore this issue by conducting 
splicing assays in 31 BRCA2 genetic variants. All variants were assessed by RT-PCR followed 
by capillary electrophoresis (EP) and direct sequencing. If assays did not produce clear-cut 
outputs (Class-2 or Class-5 according to analytical IARC guide-lines), we performed qPCR 
and/or Minigene assays. The latter were performed with a new splicing vector (pSAD) 
developed by authors of the present manuscript (Patent P201231427 CSIC). We have 
identified 3 clinically relevant Class-5 variants (c.682-2A>G, c.7617+1G>A, and c.8954-5A>G), 
and 27 analytical Class-2 variants (not inducing splicing alterations). In addition, we 
demonstrate that rs9534262 (c.7806-14T>C) is a BRCA2 splicing quantitative trail loci (sQTL).  
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Germ-line inactivating mutations in BRCA2 (MIM#600185) confer markedly increased risks of 
breast and ovarian cancer. Arguable, BRCA2 truncating mutations (PTCs) are considered 
inactivating (clinically relevant) per se (PTCs located 3’ to the last 50 nucleotides of the 
penultimate exon representing one exception). However, a high proportion of the genetic 
variants identified through clinical testing are not PTCs, but rather missense, synonymous or 
intronic changes of unknown functional effects [Spurdle et al., 2012]. Several approaches have 
been proposed to elucidate the clinical relevance (if any) of these so-called unclassified 
variants (UVs), including association with family history, co-segregation analysis, and co-
occurrence with a pathogenic mutation. These and other evidences (provided that they are 
statistically independent), can be integrated into multi-factorial models that allow likelihood 
classification of variants [Goldgar et al., 2004; Lindor et al., 2012]. Based on posterior 
probability outputs, the International Agency for Research on Cancer (IARC) working group on 
UVs proposed a 5-tier classification scheme with clinical recommendations [Plon et al., 2008]. 
According to this scheme, Class-1 variants are non pathogenic, while Class-5 variants are 
definitely pathogenic.  
In vitro assays assessing the effect of UVs on splicing (or protein activity) can be highly 
informative in the classification process, especially if multi-factorial likelihood classification is 
not feasible. In particular, in vitro splicing assays are widely used in the clinical setting [Walker 
et al, 2013], probably reflecting the fact that general approaches to predict and verify splicing 
alterations are relatively straightforward. Unfortunately, interpretation of results is often more 
challenging [Spurdle et al., 2008; Walker et al., 2013].  The IARC Working Group on UVs has 
developed guide-lines for the prediction and assessment of splicing alterations [Spurdle et al., 
2008]. Their authors adapted the IARC 5-tier clinical classification scheme (originally intended 
for clinical classification of multi-factorial model outputs) to the particular case of interpreting in 
vitro splicing results [Spurdle et al., 2008]. Due to the specific characteristics of these in vitro 
assays (such as absence of numerical outputs) major modifications were introduced, including 
the fact that this is a 4-tier classification scheme according to which, Class-2 and Class-5 
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indicate clear-cut splicing assay outputs, the first indicating that the variant allele produces the 
same transcript(s) as the wild-type allele, the latter indicating that the UV allele expresses 
major PTC transcripts. Class-1 was avoided because splicing analysis outputs per se do not 
allow discarding a pathogenic role (protein function and/or other biological features might be 
altered). Most relevant, this 4-tier is not a clinical, but rather an analytical classification 
scheme. As such, analytical Class-2, Class-3, and Class-4 do not have specific clinical 
recommendations. In this regard, analytical Class-5 is exceptional, as BRCA2 PTCs are 
considered clinically relevant per se. The analytical classification guide-lines have been 
updated recently [Walker et al., 2013]. See Supp. Table 1 for further details.  
On practical grounds, quantitative (or semi-quantitative) estimation of aberrant/normal 
transcripts ratio (as expressed from the UV allele) is mandatory for clear-cut analytical 
classification [Spurdle et al., 2008; Walker et al., 2013]. Most important, two confounding 
effects (normal expression from the wild-type allele and selective degradation of PTC 
transcripts by the NMD pathway) should be mitigated in order to produce robust outputs. For 
instance, PTC transcripts can be stabilized by performing cell cultures in the presence of 
cycloheximide (or other NMD inhibitors). Interferences from the wild-type allele can be avoided 
by developing reporter Minigene assays. Unfortunately, these time-consuming approaches 
cannot be easily implemented into the routine of a Clinical Diagnostics Laboratory.  
Here we show that incorporating capillary EP and direct sequencing of exonic SNPs into the 
analysis of otherwise conventional splicing assays (RT-PCRs of fresh-blood isolated RNAs) is 
able to generate clear-cut analytical outputs (so to speak, analytical Class-2 and Class-5 
outputs according to the IARC guide-lines). However, we show as well that some 
variants/carriers demand more specific (and time-consuming) analytical approaches (such as 
dedicated mini-genes or qPCR).  
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As a proof of principle, we analyzed the influence of 31 BRCA2 variants (Table 1) on splicing 
(see on-line methods and Supp. Table S2 for further details). In silico predictions are shown in 
Table 1 (splice sites) and Supp. Table S3 (enhancer and silencers). However, we performed in 
vitro splicing assays regardless of in silico predictions. Furthermore, we analyzed not only 
BRCA2 UVs, but also clinical Class-1 and clinical Class-5 variants. We did it because we are 
interested in finding not only novel BRCA2 splicing mutations relevant in the clinic, but also 
non-pathogenic splicing alterations (if any) that might contribute to elucidate the sometimes 
complex relationship between splicing alterations and disease. Last but not least, we are 
interested in evaluating whether conventional splicing assays provide clear-cut analytical 
outputs according to existing guide-lines.  
As far as we know, BRCA2 c.682-2A>G is a novel variant not previously reported. Capillary 
EP analyses in carriers (33 cycles RT-PCR assays) detected (in addition to the full-length) a 
264nt peak representing roughly 10% of the overall signal (Figure 1A). Interestingly, 45 cycles 
RT-PCR assays revealed five additional peaks (Figure 1B). Size-callings were compatible with 
exon 9 skipping (264nt peak), and activation of five cryptic acceptor sites (CASs) located in 
intron 8 and exon 9 (Figures 1B and 1C). All CASs were supported by in silico predictions 
(Figure 1C). Direct sequencing demonstrated exon 9 skipping, and CAS4 activation (Figure 
1D). Other CAS activation events were not sequenced due to the low abundance of the 
corresponding RT-PCR products. These should be considered putative CAS activation events 
inferred from capillary EP size-calling. Similar peak patterns were observed in four additional 
variant carriers (Figure 1E), but not in control samples (data not shown). Importantly, all 
aberrant splicing events produce PTC transcripts. Segregation analysis together with direct 
RT-PCR sequencing at informative loci (rs9534262 and rs1799955) demonstrated that full-
length BRCA2 expression was wild-type allele specific (Supp. Figure S1).  Taking together, the 
data qualifies for inclusion into analytical Class-5  (see Supp. Table 1).  
BRCA2 c.7617+1G>A has been reported previously in Spanish [Gutierrez-Enriquez et al., 
2009] and Danish [Thomassen et al., 2011]  hereditary breast and ovarian cancer families. 
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Both studies detected exon 15 skipping (a PTC event) in variant carriers, but bi-allelic wild-
type expression was not investigated (analytical Class-4 outputs). Yet, co-segregation studies 
performed in Danish families supported a pathogenic role for this variant (clinical Class-5 
variant). We have performed splicing assays in 6 BRCA2 c.7617+1G>A carriers. As shown in 
Supp. Figure S2, capillary EP analysis (33 cycles RT-PCR) detected, in addition to the full-
length, a 182nt shorter peak compatible with exon15 skipping. Direct sequencing confirmed 
the skipping event (Supp. Figure S2). Capillary EP data (semi-quantitative) shows roughly 
identical expression levels of full-length and ∆15 transcripts. The data is compatible with the 
UV allele causing complete (or near complete) exon skipping, but does not prove it. This is so 
because capillary EP estimates (at best) the ratio between steady-state levels (accumulation) 
of wild-type and variant transcripts in carriers. This in turn might reflects a combination of 
multiple underlying processes, including reduced (or unusually higher) transcription rate from 
the UV allele, instable (or unusually stable) UV transcripts, and wild-type transcripts arising 
from the UV allele. Yet, segregation analysis together with direct RT-PCR sequencing at one 
informative locus (rs1799955) revealed that full-length BRCA2 expression was indeed wild-
type allele specific (Supp. Figure S2). Overall, the data qualifies for inclusion into analytical 
Class-5 (see Supp. Table 1). We have identified eight Spanish families carrying BRCA2 
c.7617+1G>A (Supp. Figure S3). Genotyping of STRs and SNPs markers detected a common 
haplotype in carriers from all eight families, suggesting a founder effect (Supp. Table S4).  
BRCA2 c.8954-5A>G has been identified recently in Spanish Hereditary Breast and Ovarian 
Cancer families [de Juan Jimenez et al., 2013], but splicing defects if any) were not 
investigated. The change is reported in the Universal Mutation Database (UMD) as a clinical 
Class-3 variant (http://www.umd.be/BRCA2/). We have performed splicing assays in two 
BRCA2 c.8954-5A>G carriers. Agarose gel electrophoresis showed a single RT-PCR product 
both in controls and carriers (data not shown), but capillary EP detected an additional peak 
(+4nt) in carriers (Supp. Figure S4). Direct sequencing revealed a PTC transcript in which the 
last 4nt of intron 22 have been incorporated into BRCA2 exon 23 (Supp. Figure S4).  
Measured by capillary EP, the aberrant mRNA represents roughly 30% of the overall signal. 
Page 7 of 50
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
7 
 
The data is compatible with wild-type expression arising from the UV allele, but does not prove 
it (as discussed above). Since bi-allelic wild-type expression was not tested due to lack of 
informative loci, it is not possible to classify the output into any specific analytical category 
(Class-4 or Class-5?) according to the 2008 guide-lines. However, the very same output 
qualifies for analytical Class-4 according to the 2013 guide-lines (see Supp. Table 1). 
Interestingly, HSF analysis predicted a de novo acceptor site at position c.8954-4 without 
disrupting exon 23 native acceptor site (Table 1), thus suggesting a mechanism through which 
c.8954-5A>G might indeed contribute to normal splicing. To investigate wild-type expression 
arising from the UV allele, we used a reporter Minigene assay (see on-line methods). The 
analysis revealed that c.8954-5G does not produce full-length mRNA (Supp. Figure S5). As a 
whole, our data qualifies for inclusion into analytical Class-5. We have identified four Spanish 
families carrying this mutation (Supp Figure S6). Haplotype analysis identified a 1.28Mb 
shared haplotype in all carriers, suggesting a founder effect (Supp. Table S4). 
Similar assays performed in 23 additional BRCA2 variants did not detect aberrant transcripts, 
despite the fact that we used high sensitivity capillary EP analysis. BRCA2 bi-allelic expression 
was confirmed in all cases (Supp. Figures S7 to S18). Taking together, all 23 studies qualify 
for inclusion into analytical Class-2 (see Supp. Table 1). Yet, it is important to remark that 
analytical Class-2 per se do not have a definite role in the clinical classification of BRCA2 
variants.  
Not surprisingly, splicing analysis tends to be overlooked in BRCA2 PTC mutation carriers. 
However, these (as other mutations) might induce splicing alterations (perhaps even 
regenerating a full-length open reading frame). This phenomenon is probably unlikely, but is 
certainly real. For instance, it has been reported that c.145G>T (p.Glu49Ter), a PTC mutation 
located in BRCA2 exon 3, enhances exon 3 skipping (an in-frame splicing isoform), illustrating 
a complex interplay between RNA and protein effects of potential clinical interest [Sanz et al., 
2010]. We have included in our analysis five BRCA2 variants predicted to express PTC 
transcripts, including four pathogenic (clinical Class-5) mutations (c.1773_1776del, 
c.3264dupT, c.8010_8032del22, and c.9026_9030del) and one benign (clinical Class-1) 
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change (c.9976A>T). However, capillary EP analysis of RT-PCR assays (agarose in the case 
of c.3264dupT) did not detect splicing alterations. With the single exception of 
c.9026_9030del, PTC transcripts were detected at similar levels as wild-type transcripts, 
suggesting (albeit not proving) that they are not targeted by the NMD pathway (Supp. Figures 
S19 and S20).  Since wild-type expression arising from PTC alleles can be discarded per se, 
all five splicing results qualify for analytical Class-5 according to existing guide-lines (Supp. 
Table 1), regardless of the fact that none of these variants affects splicing.  
We have identified five common (MAF>0.1) BRCA2 variants in our cohort (Table 1).  In silico 
analyses did not predict splicing alterations, with the single exception that (according to 
MaxEnt), c.7806-14T>C (rs9534262) produces a slight reduction of the exon17 acceptor site 
score (Table 1). Interestingly, two “naturally occurring” alternative splicing events (∆17,18 and 
∆18)  have been described in this region [Walker et al., 2010]. Capillary EP did not detect 
novel transcripts in c.7806-14T>C carriers, but suggested that BRCA2 ∆17,18 was slightly up-
regulated (data not shown). Hence, we decided to explore the role of c.7806-14T>C in 
alternative splicing regulation by qPCR (see on-line Methods). Quantification experiments 
were performed in 7 T/T, 20 T/C, and 11 C/C carriers. The expression level of BRCA2 ∆17,18 
(relative to overall BRCA2 expression level) was low (∆CT = 5.19±0.59), reflecting the fact that 
BRCA2 ∆17,18 is a minor alternative splicing isoform. Yet, the ANOVA test identified 
differences associated with each genotype (p=0.006). Post-hoc test demonstrated higher 
levels of BRCA2 ∆17,18  in C/C carriers compared with T/T carriers (p=0.004) (Supp. Figure 
S21). To confirm that the C allele is indeed functionally related, and not just in linkage 
disequilibrium with a true splicing regulatory element, we performed further analysis in a 
reporter minigene (exons 16 to 20 of BRCA2) based on the new splicing vector pSAD® 
(Consejo Superior de Investigaciones Científicas). In this model, the c.7806-14C reporter 
minigene showed relative increased levels of both ∆17,18 and ∆18 isoforms if compared with  
c.7806-14T reporter minigene (Supp. Figure S22). Overall, the data indicates that rs9534262 
is a bonafide BRCA2 splicing quantitative trait locus (sQTL). Since BRCA2 ∆17,18 and 
BRCA2 ∆18 are PTC splicing isoforms, we hypothesized that rs9534262 might be associated 
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with breast cancer risk. To test it, we performed case-control association studies and Kaplan-
Meier survival analyses. Overall, these analyses do not support an association with risk (Supp. 
Figure S23). 
  
In summary, we have performed routine in vitro splicing assays (blood RNA based RT-PCR 
experiments) in 31 BRCA2 genetic variants, producing 29 clear-cut analytical outputs. Of 
these, two Class-5 (c.682-2A>G and c.7617+1G>A) are clinically relevant findings per se. By 
contrast, neither c.8954-5A>G nor c.7806-14T>C (rs9534262) routine in vitro splicing assays 
resulted in clear-cut analytical classification. The former is of particular clinical relevance, since 
subsequent dedicated assays (a reporter Minigene) demonstrated that BRCA2 c.8954-5A>G 
is indeed a clinically relevant Class-5 variant.  
Analysis of c.7806-14T>C (rs9534262) with dedicated assays (reported Minigene and qPCR) 
produced results that qualify for analytical Class 4 (2008 guide-lines), or analytical Class-3 
(2013 guide-lines) (see Supp. Table 1). However, BRCA2 rs9534262 is a clinical Class-1 
variant (MAF is close to 0.5 in many populations). Similarly, splicing analysis in c.9976A>T 
(p.Lys3326Ter) carriers produced an analytical Class-5 output, despite the fact that this is a 
clinical Class-1 variant based on posterior probability analysis (http://brca.iarc.fr). These two 
examples illustrates the fact that the 4-tier classification scheme of splicing assays outputs is 
more related to the “analytical quality” and “interpretation” of UV splicing assays than to the 
actual probability of being pathogenic.  
Undoubtedly, sequencing informative exonic SNPs (testing bi-allelic expression) is critical in 
order to produce clear-cut routine in vitro splicing assays. In addition, we show that 
incorporating capillary EP into the analysis provides highly informative analytical data (both 
high-resolution size-calling and high-sensitivity detecting RT-PCR products). These two 
features were critical in order to characterize the rather complex splicing outcome observed in 
BRCA2 c.682-2A>G carriers. This variant induces the expression of several (probably six) 
different aberrant transcripts. As a result, the “aberrant signal” is split into different components 
Page 10 of 50
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
10 
 
(different RT-PCR products), none of which is detectable by conventional EtBr-stained 
agarose gel analysis (data not shown). Equally relevant, capillary EP ensures that Class-2 
outputs are indeed clear-cut negative results. Capillary EP provides not only high-resolution 
size-calling and high-sensitivity, but also semi-quantitative information (area under the peaks) 
that might be useful for analytical purposes. For instance, it allowed us to identify c.7806-
14T>C (rs9534262) as a candidate sQTL for further dedicated assays.  
We have performed several routine in vitro splicing assays in carriers of UV variants with low 
prior probability (according to in silico predictions) of finding an alteration; a conservative 
approach that we nonetheless recommend in the clinical setting. Undoubtedly, in silico 
analyses might provide high accuracy predictions, but they do not detect all splicing defects, 
especially in variants located outside the 5’ and 3’ consensus sites (Houdayer et al., 2012). 
Yet, we think that in silico analyses have important roles in the clinic. For instance, they assist 
with prioritizing variants for dedicated splicing assays (such as reporter Minigenes) in cases 
where routine assays do not produce clear-cut outputs, or in cases in which routine assays are 
not feasible (i.e. lack of fresh blood RNA).    
In conclusion, we show that incorporating capillary EP and direct sequencing of exonic 
informative SNPs to, otherwise, conventional fresh blood-based RT-PCR splicing assays often 
provides high-quality results that allow systematic analytical classification according to existing 
guide-lines.  
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Figure Legends 
 
Figure 1 
 
A) Capillary EP analysis (33 cycles RT-PCR assays) identifies one aberrant transcript in 
carriers. B) Capillary EP (45 cycles RT-PCR assays) identifies five additional aberrant 
transcripts. Size callings are compatible with exon 9 skipping (225 nt peak), and activation of 
five cryptic acceptor sites (CASs). C) A BRCA2 sequence including exon9 (capital letters) and 
intronic boundaries is shown. Five CASs are displayed (bold letters). Human Splicing Finder 
(HSF) scores (% of wild-type acceptor site score) are indicated in brackets. D) Direct 
sequencing of RT-PCRs demonstrates exon9 skipping and CAS4 activation. E) 45 cycle PCR 
assays allowed semi-quantitative analysis of aberrant transcripts. The chart represents the 
relative amount of each aberrant transcript compared with the overall aberrant transcript 
signal, as determined in five carriers (mean and SD are shown) 
 
 
 
 
 
 
 
Page 15 of 50
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  Table 1. Splicing analysis in 35 BRCA2 variants 
 In Silico Splicing Analysis
3
 Analytical classification of In Vitro Splicing Assays Outputs
4
 
Location HGVS description
1
 dbSNP MAF
2 
HSF MaxEnt Published Data Routine Assay Minigene qPCR 
Intron 1 c.-39-26G>A - .0004 no effect no effect - Class-2 - - 
Intron 4 c.426-89T>C rs3783265 .022 (c.426-81; 86.04%) no effect - Class-2 - - 
Intron 6 c.516+14C>T rs182828913 .0016 no effect no effect Class-2
5
 Class-2 - - 
Intron 7 c.631+25C>T - .0008 no effect no effect - Class-2 - - 
Exon 8 c.680C>T (p.Ala227Val) rs149565664 .0004 -0.57% -3.04% - Class-2 - - 
Intron 8 
c.681+69C>T ‡ - .0004 no effect no effect - Class-2 - - 
c.682-2A>G  ‡ - .0008 -33.39% -112.46% - Class-5 - - 
Exon 10 
c.1114A>C (p.His372Asn) rs9534262 .11 no effect no effect Class-2
6
 - - - 
c.1773_1776del (p.Ile591fs) rs80359305 .0004 no effect no effect - Class-5 - - 
Exon 11 
c.3264dupT (p.Gln1089fs) rs80359380 .0097 (c.3268; 103.25%) (c.3283; 7.52%) - Class-5 - - 
c.3396A>G (p.Lys1132=) rs1801406 .25 no effect no effect - - - - 
c.3807T>C (p.Val1269=) rs543304 .14 no effect no effect - - - - 
c.6825G>A (p.Glu2275=)  ‡ - .0004 no effect no effect - Class-2 - - 
Exon 12 c.6928A>C (p.Thr2310Pro) ‡ - .0004 (c.6935; 96.34%) no effect - Class-2 - - 
Exon 14 c.7242A>G (p.Ser2414=) rs1799955 .20 no effect no effect - - - - 
Intron 14 c.7435+8A>G ‡ - .0004 (c.7436+7; 92.39%) no effect - Class-2 - - 
Exon 15 c.7469T>C (p.Ile2490Thr) rs11571707 .0024 no effect no effect - Class-2 - - 
Intron 15 c.7617+1G>A
7
 - .0016 -29.43% -83.47% non classifiable (Class-4)
8,
* Class-5 - - 
Exon 16 
c.7626G>A (p.Thr2542=) rs61754138 .0004 no effect - no effect - Class-2 - - 
c.7796A>G (p.Glu2599Gly) ‡ - .0004 (c.7796; 88.03%) no effect - Class-2 - - 
Intron 16 c.7806-14T>C rs9534262 .40 no effect -4.68% - non classifiable** Class-4(Class-3) Class-4(Class-3) 
Intron 17 
c.7976+5G>T ‡ - .0004 -16.83% -74.19% - Class-2 - - 
c.7976+57G>C - .0004 no effect no effect - Class-2 - - 
Exon 18 
c.8010_8032del (p.Ala2671fs) rs80359690 .0004 no effect no effect - Class-5 - - 
c.8149G>T  (p.Ala2717Ser) rs28897747 .0004 (c.8168; 55.22%) no effect - Class-2 - - 
 
Exon 20 
c.8503T>C (p.Ser2835Pro) rs11571746 .0024 no effect no effect - Class-2 - - 
c.8524C>T (p.Ar2842Cys)
9
 rs80359104 .0004 (c.8535; 88.19%) no effect - Class-2 - - 
 c.8592C>T (p.Ala2864=) - .0004 (c.8591; 79,82%) no effect - Class-2 - - 
Exon 22 
c.8850G>T (p. Lys2950Asn) rs28897754 .0008 no effect no effect - Class-2 - - 
c.8851G>A (p.Ala2951Thr) rs11571769 .0004 no effect no effect - Class-2 - - 
Intron 22 c.8954-5A>G - .0008 -0.08 % (c.8954-4; 103.97%) -43.77 % (c.8954-4; 98.45%) non classifiable (Class-4)
10,
 * non classifiable (Class-4)* Class-5 - 
Exon 23 
c.9004G>A (p.Glu3002Lys)
9,11
 rs80359152 .0004 (c.9008; 87.90%) (c.9008; 38.16%) - Class-2 - - 
c.9026_9030del ( p.Thr3009fs) rs80359741 .0020 no effect no effect - Class-5 - - 
c.9038C>T (p.Thr3013lle) rs28897755 .0008 no effect no effect Class-2
6
 Class-2 - - 
Exon 27 c.9976A>T (p.Lys3326Ter) rs11571833 .009 no effect no effect - Class-5 - - 
1 
Description according to HGVS guide-lines (http://www.hgvs.org/mutnomen). Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the GeneBank reference sequence NM_000059.3.   
 
2  
MAF in index cases from HBOC families (N=2558 chromosomes).
3
 De novo splice site predictions are shown in brackets.
 4
 Both 2008 [Spurdle et al, 2008] and 2013 [Walker et al, 2013] guide-lines have been considered. If discrepant, 2013 Class is 
shown in brackets.
 
Published data was classified by authors of the present manuscript. 
5 
[Bonnet et al., 2008]. 
6 
[Sanz et al., 2010]. 
7
 Segregation analyses supported that this is indeed a Class-5 variant [Thomassen et al., 2011].   
8 
[Gutierrez-Enriquez et 
al., 2009; Thomassen et al., 2011]. 
9 
Inactivating in protein functional assay [Guidugli et al., 2013]. 
10 
[Menendez et al., 2012]. 
11 
Inactivating in protein functional assays [Biswas et al., 2012]. * UV allele contribution to wild-type expression was not tested. 
** Poor quality semi-quantitative data does not allow classification. ‡ Novel variants submitted to the Breast Informative Core (BIC) database (http://research.nhgri.nih.gov/bic/).  
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A) Capillary EP analysis (33 cycles RT-PCR assays) identifies one aberrant transcript in carriers. B) Capillary 
EP (45 cycles RT-PCR assays) identifies five additional aberrant transcripts. Size callings are compatible with 
exon 9 skipping (225 nt peak), and activation of five cryptic acceptor sites (CASs). C) A BRCA2 sequence 
including exon9 (capital letters) and intronic boundaries is shown. Five CASs are displayed (bold letters). 
Human Splicing Finder (HSF) scores (% of wild-type acceptor site score) are indicated in brackets. D) Direct 
sequencing of RT-PCRs demonstrates exon9 skipping and CAS4 activation. E) 45 cycle PCR assays allowed 
semi-quantitative analysis of aberrant transcripts. The chart represents the relative amount of each aberrant 
transcript compared with the overall aberrant transcript signal, as determined in five carriers (mean and SD 
are shown)  
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Patients and Samples.  
All variants under study were first identified through clinical testing in index cases of high risk 
hereditary breast and ovarian cancer families undergoing genetic counseling according to 
Spanish National Health System recommendations (N=1279). According to the frequency 
observed in the index case cohort, we refer throughout the text to rare (f<0.1) and common 
(f>0.1) BRCA2 variants. We have performed in vitro RNA analysis in index cases (or 
relatives) carrying the genetic variants of interest. In addition, rs9534262 (c.7806-14T>C)  
has been genotyped in 376 healthy control individuals, a consecutive series of 173 women 
diagnosed of breast cancer, and 438 index cases from BRCAX families (high risk families 
negatives for BRCA1 and BRCA2 germ-line mutations after comprehensive genetic testing). 
The BRCAX cohort has been extensively described elsewhere [de Garibay et al., 2013; Dosil 
et al., 2010]. All participants signed an informed consent. The study was approved by the 
Ethics Committee of the participating institutions.  
 
BRCA2 sequence variants description.  
All BRCA2 genetic variants are described according to HGVS guide-lines 
(http://www.hgvs.org/mutnomen). Nucleotide numbering reflects cDNA numbering with +1 
corresponding to the A of the ATG translation initiation codon in the GeneBank reference 
sequence NM_000059.3 
 
In silico splice predictions  
Consensus splice sites predictions were performed with HSF and MaxEnt algorithms. 
Splicing enhancer predictions were performed with ESE finder, RESCUE-ESE, PESE and 
EIE algorithms. Similarly, splicing silencer predictions were analyzed with ESS, Fas-ESS, 
PESS and IIE algorithms. All analyses were performed on-line with Human Splicing Finder 
version 2.4.1 (default settings).  
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Blood-based RT-PCR In Vitro Splicing Assays (Routine Assay). 
RNAs were extracted from fresh blood using a MagnaPure Compact workstation and Magna 
Pure RNA kits according to the manufacturer’s instructions (Roche Diagnostics). RT was 
performed with 300ng of RNA and the PrimeScript RT kit (Takara Biotechnology) following 
manufacturer’s protocol. Depending on the interrogated variant, cDNAs were amplified with 
different combinations of forward and reverse primers (Supp. Table 1). Amplicons were 
designed taking into consideration both in silico predictions and “naturally occurring” 
alternative splicing events. The later might be relevant for the correct analysis of BRCA2 
splicing variants, as has been previously shown for BRCA1 splicing variants [Dosil et al., 
2010]. Fluorescent PCRs were performed with FastStart Taq (Roche Diagnostics) in a final 
volume of 25 µL that contained 1 µL of cDNA. Samples were denatured at 95º for 10 min, 
followed by 45 cycles consisting of 95º for 30 sec, 58 º for 30 sec, and 72º for 30 sec, and 
final extension step at 72º for 7 min. For semi-quantitative analysis, the number of PCR 
cycles was reduced to 33. RT-PCR products were analyzed by capillary electrophoresis on 
an ABI3130 automated sequencer (Life Technology). Depending on the expected sizes, LIZ-
500 or LIZ-1200 (Life Technology) was used as internal size-standard. Size-calling and peak 
areas (semi-quantitative assays) were analyzed with the Genemapper software v.3.7 (Life 
Technology). Bi-allelic expression was analyzed by direct sequencing of RT-PCR reactions 
performed at informative (heterozygous) loci: either the interrogated variant itself (exonic 
variants) or linked exonic SNPs (in the case of intronic variants). Cycle sequencing was 
performed using the BigDye Terminator v3.1 Cycle Sequencing kit (Life Technology).  
 
Minigene assays  
Construction of Minigenes:  
The construction of the minigene containing BRCA2 exons 23 and 24 and flanking intronic 
sequences (MGBR2_Ex23-24) inserted into the splicing vector pSPL3b was previously 
described [Acedo et al, 2012]. The minigene containing exons 16 to 20 of the BRCA2 
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(MGBR2_Ex16-20) gene was constructed in three sequential cloning steps in a new splicing 
vector derived from pSPL3 called pSAD (Patent P201231427 CSIC, Priority Patent 
Application filed; Acedo et al, manuscript in preparation): exons 17+18 in a single fragment 
(1,556 bp; intron 17= 485 bp), exon 16 (805 bp) and exons 19+20 in a single fragment (1165 
bp; intron 19= 398 bp). These sequences were amplified with the Phusion Hot Start II High 
Fidelity DNA Polymerase (Thermo Fisher Scientific, Waltham, MA) following the 
manufacturer’s instructions, and using the following primers: 
for exons 17+18: 
mgbr2_ex17fw, 5'GCTCTAGAACTAGTGGATCCCCCGGTCAGTATGATACTTTGATACATGT3' 
mgbr2_ex18rev, 5'ATAAGCTTGATATCGAATTCCTGCAGTGGAATAGGGATCTGATCAA3', 
for exon 16: 
mgbr2_ex16fw, 5'GCTCTAGAACTAGTGGATCCCCCGGCCCTTTTGTTTCCCATCTAAGT3' 
mgbr2_ex16rev, 5'GACATGTATCAAAGTATCATACTGAATAAATGCCTAAGAAAAATGT3’ 
For exons 19+20: 
mgbr2_ex19fw, 5'CACACACTCGAGATAGCATTAAGAACTTGTAGCA3' 
mgbr2_ex20rev, 5'CACACAGGTACCATTACAAATGGCTTAGACCTGA3'  
For cloning purposes a 5’ tail (underlined) was added to each primer. The final structure of 
the insert of the minigene from the 5’ to the 3’ end was: ivs15 (333 bp) - exon 16 (188 bp)- 
ivs16 (234 bp)- // - ivs16 (181 bp) - exon 17 (171 bp) – ivs17 (485 bp) – exon 18 (355 bp) – 
ivs18 (314 bp)-  // - ivs18 (235 bp) – exon 19 (156 bp) – ivs19 (398 bp) – exon 20 (145 bp)– 
ivs20 (207 bp). Introns 16 (4,595 bp) and 18 (6,853 bp) were too large so they were 
shortened to facilitate cloning. All the new constructs were sequenced with the Big Dye 3.1 
Sequencing Kit (Life Technologies) to confirm the fidelity of cloned sequences. 
Site directed mutagenesis: 
Mutagenesis was carried out according to the PCR mutagenesis protocol 
(http://www.methodbook.net/pcr/pcrmut.html) with Pfu Turbo DNA polymerase (Agilent, 
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Santa Clara, CA, USA). Wild type (wt) minigenes MGBR2_Ex23-24 and MGBR2_Ex16-20 
were used as templates to generate DNA variants. 
For c.7806-14T>C of intron 16 primers used were 
5' TTTATGATAATATTCTACCTTTATTTGTTCAGGGCTC 3'   
5' GAGCCCTGAACAAATAAAGGTAGAATATTATCATAAA 3' 
For c.8954-5A>G of intron 22 primers used were 
5' TCTTTCTCATCTTTCTCCAGACAGTTATACTGAGTATTTG 3'  
5' CAAATACTCAGTATAACTGTCTGGAGAAAGATGAGAAAGA 3' 
Transfection of HeLa cells:  
Approximately 105 HeLa cells (human cervical carcinoma) were grown to 90% to 95% 
confluency in 0.5 mL of growth medium (DMEM, 10% fetal bovine serum, 1% glucose and 
1% penicillin/streptomycin) in four-well plates (Nunc, Roskilde, Denmark). Cells were 
transfected with 1 µg of plasmid minigene and 2 µL of Lipofectamine 2000 (Life 
Technologies) following the manufacturer’s protocol. RNA was purified 24-48 hours after 
transfection with Nucleospin-RNA-II (Macherey-Nagel, Düren, Germany) that includes on-
column rDNAse treatment and quantified in a Nanodrop 1000 spectrophotometer (Thermo 
Fisher Scientific) 
RT-PCR of minigenes:  
Retrotranscription was carried out with 200 ng of RNA and the transcriptor first strand cDNA 
synthesis kit (Roche Diagnostics). Fluorescent RT-PCRs were performed in triplicate in a 
final volume of 20 µL that contained 2 µL of cDNA and the flanking primers of constitutive 
exons of pSPL3, SD6-PSPL3_RTFW (FAM-5’ TCACCTGGACAACCTCAAAG 3’) and SA2-
PSPL3_RTREV (5’ TGAGGAGTGAATTGGTCGAA 3’). Samples were denatured at 94°C for 
two minutes, followed by 25-30 cycles consisting of 94°C for 20 seconds, 58°C for 20 
seconds, and 72°C for 30-90 seconds, and a final extension step at 72°C for two minutes. 
The PCR products were analyzed by capillary electrophoresis. Expected sizes of the RT-
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PCR products were 488 bp and 1199 bp for minigenes MGBR2_Ex23-24 and MGBR2_Ex16-
20, respectively 
 
Relative quantification of  BRCA2 ∆17,18 expression level. 
The relative expression level of BRCA2 ∆17,18 was measured by real-time PCR with a 
dedicated FAM-labeled TaqMan gene expression assay. The assay was designed and 
synthesized using the Assay-by-Design service (Life Technology) that includes proprietary 
specificity and amplification efficiency QC testing. As endogenous control, we used the VIC-
labeled Custom TaqMan gene expression assay Hs01037420_m (Life Technology) that 
targets BRCA2 exon 24 (since no BRCA2 ∆24 splicing isoform has been reported, BRCA2 
exon 24 probably reflects the overall BRCA2 expression level). Both assays were performed 
in a single tube reaction including 1 µL of cDNA, 1X TaqMan Universal PCR MasterMix (Life 
Technology) and 1X TaqMan assays. Experiments were performed in a 7500 Fast Real-Time 
PCR system (Life Technology) with default thermal cycling conditions (Life Technology). For 
quantification purposes, we measured ∆CT, defined as CT BRCA2∆17,18 – CT BRCA2e24. 
Therefore, ∆CT reflects the expression level of BRCA2 ∆17,18 relative to the overall 
expression level from the same locus. ∆CT was analyzed in triplicate in all tested samples.  
 
Haplotype analysis of recurrent variants 
Haplotype analysis was performed with up to 9 short tandem repeats (STR) covering 14.4Mb 
of chromosome 13 surrounding the BRCA2 gene. Primer sequences, order of markers and 
physical distances among D13S260, D13S1699, D13S1698, D13S1697, D13S1701, 
D13S1715, D13S1493, D13S267, and D13S1694 were obtained from the Ensembl database 
(http://www.ensembl.org). Polymerase chain reaction (PCR) products of STR markers were 
generated using fluorescently labelled primers. Size-calling was performed by capillary 
electrophoresis.  Additionally, 3 BRCA2 SNPs (rs1799943, rs144848, and rs9534262) were 
genotyped by HRMA.  
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Statistical Analyses.  
BoxPlots, Kaplan-Meyer survival analysis, chi-square, and ANOVA test were performed with 
SPSS v13.0 software.  
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Supp. Figure S1. A family carrying the BRCA2 variant c.682-2A>G is displayed. Segregation 
analysis allowed us to determine the phase between the variant allele and two SNPs located in 
BRCA2 exon 10 (rs9534262) and exon14 (1799955). Direct sequencing of RT-PCR assays (33-
cycle PCR)  performed with RNA isolated from individual ID_1 showed that mutant allele 
contribution to overall BRCA2 expression (if any) is minimal. 
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Supp. Figure S2.  A, B) capillary EP analysis (33 cycles RT-PCR) revealed an aberrant 
transcript 182nt shorter than wt in c.7617+1G>A carriers, suggesting BRCA2 exon 15 skipping. 
Direct sequencing confirmed exon 15 skipping. C) An informative locus in exon 14 (rs1799955) 
allowed us to demonstrate that the variant allele does not contribute to full-length expression. 
Note that RT-PCR products generated with an exon15 reverse primer (right) are full-length 
specific. Segregation analysis allowed us to determine the phase between the variant allele and 
rs1799955 (data not shown). 
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Supp. Figure S3.  Eight Spanish families carrying the BRCA2 genetic variant c.7617+1G>A. Numbered Individuals were included in the haplotype analysis 
(See Supp. Table S2). 
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Supp. Figure S4.  Capillary EP analysis of the RT-PCR with primers at exon 21 and 24 in a c.8954-5A>G carrier. Direct sequencing demonstrates an 
insertion corresponding to the last 4nt of intron 22. 
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Supp. Figure S5. Splicing outcomes of variants of exon 23 of BRCA2 in minigene 
MGBR2_Ex23-24. RT-PCR products labelled with FAM (blue peaks) of wild type and mutant 
minigenes were run in an ABI3130 sequencer with Genescan ROX 500 (red peaks) as size 
standard. The different RNA isoforms are indicated. A) Wild type minigene; B) c.8954-3C>G 
(intron 22); C) c.9117+1G > A c; D) c.8954-5A>G; E) Sequencing of isoforms produced from 
c.8954-5A>G. 
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Supp. Figure S6.  Four Spanish families carrying the BRCA2 genetic variant c.8954-5A>G. Numbered Individuals were included in the haplotype analysis 
(See Supp. Table S3). 
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Supp. Figure S7.  a) RT-PCR with primers located in exons 1 and 4 shows a similar splicing 
pattern in controls and c.-39-26G>A carrie s, with the presence of full-length and ∆3 BRCA2 
transcripts. b) Capillary EP analysis of semi-quantitative RT-PCR assays (33 cycle PCR)  
shows no obvious differences in the amount of ∆3 BRCA2 transcripts in c.-39-26G>A carriers. 
c) Bi-allelic expression was confirmed by direct sequencing of an RT-PCR assay containing an 
informative locus (rs144848).  
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Supp. Figure S8. Capillary EP analysis of semiquantitative RT-PCR with primers located at 
exons 2 and 8 shows similar patterns of splicing in controls, c.426-89T>C, c.516+14C>T and 
c.631+25C>T carriers. Full-length, ∆3 and ∆6q7 BRCA2 transcripts were detected in all 
samples at similar levels. Bi-allelic expression was confirmed by direct sequencing of RT-PCR 
assays containing informative loci (rs1799944, rs766173, rs1799943). 
Page 31 of 50
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Supp. Figure S9. Capillary EP analysis of semi-quantitative RT-PCR assays (33 cycle PCR) performed with primers 
located at exon 4 and 10 shows similar patterns of splicing in wt controls and c.680C>T carriers. Full-length and ∆6q7 
BRCA2 transcripts were detected in all samples at similar levels. Direct sequencing of RT-PCR assays confirmed bi-
allelic expression in c.680C>T carriers.  
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Supp. Figure S10. Capillary EP analysis of RT-PCR assays performed with primers located in exons 7 and 10 shows 
the presence of a single transcript both  in wt controls and one c.681+69C>T carrier. Bi-allelic expression was 
confirmed by direct sequencing (reverse strand) of RT-PCR assays containing an informative locus in exon 14 
(rs1799955).  
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Supp.  Figure S11. RT-PCR with primers located in exons 11 and 12 (E11.29-S and E12-FAM-AS) shows the 
presence of a single transcript both in wt controls and one c.6825G>A carrier. Direct sequencing confirmed bi-allelic 
expression in variant carriers. 
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Supp.  Figure S12.  RT-PCR with primers located in exons 12 and 15 (E12-S and E15-FAM-AS) shows the presence 
of a single transcript in wt controls and one c.7435+8A>G carrier. Bi-allelic expression was confirmed by direct 
sequencing of RT-PCR assays containing an informative locus at exon (rs1801406).  
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Supp.  Figure S13.  a) RT-PCR with primers located at exon 14 and 16 (E14.2-S and E16.1-AS) shows the presence 
of a single transcript in control and c.7469T>C carrier. b) Sequencing of this product confirms the expression of both 
alleles. 
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Supp.  Figure S14 a) RT-PCR with primers located at exon 15 and 17 (E15.2-S and E17.1-AS) shows the presence 
of a single transcript in controls, c.7796A>G carrier and c.7626G>A carrier. b) Sequencing of these products confirms 
the expression of both alleles in all cases. 
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Supp. Figure S15. Semiquantitative RT-PCR with primers located at exon 16 and 19 shows similar splicing patterns 
in controls, c.7976+57G>C, c.7976+5G>T and c.8149G>T carriers. Full-length and ∆17,18 BRCA2 transcripts were 
detected in all samples at similar levels. Bi-allelic expression was confirmed by direct sequencing of RT-PCRs 
containing the BRCA2 variant (c.8149G>T), or in the case of intronic variants, an informative exonic locus (rs144848).   
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Supp.  Figure S16. RT-PCR with primers located at exon 19 and 22 (E19-S and E22-FAM-AS) shows the presence 
of a single transcript in c.8503T>C, c.8524C>T, and c.8503T>C carriers. Direct sequencing of RT-PCR products 
confirmed the expression of both alleles. 
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Supp. Figure S17. RT-PCR with primers located at exon 19 and 23 (E19-S and E23-FAM-AS) shows the presence of 
a single transcript in wt control, c.8850G>T and c.8851G>T carriers. Direct sequencing confirmed bi-allelic expression.  
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Supp.  Figure S18. RT-PCR with primers located at exon 21 and 24 (E21-S and E24-FAM-AS) shows the presence 
of a single transcript in control, c.9004G>A and c.9038C>T carriers. Direct sequencing confirmed bi-allelic expression. 
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Supp. Figure S19 Splicing analysis in carriers of three different BRCA2 PTC mutations did not identify splicing 
alterations. However, all predicted PTC transcripts were detected.  With the single exception of p.Tyr3009fs, PTC 
transcripts were detected at similar levels than wt transcripts.  
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Supp. Figure S20 Splicing analysis in carriers of two different BRCA2 PTC mutations did not identify splicing alterations. PTC transcripts were detected at similar levels than 
wt transcripts (sequencing data).  
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Supp. Figure S21. qPCR analysis of BRCA2 ∆17,18 splicing isoform using BRCA2 exon 24 expression (a proxy for 
overall BRCA2 expression level) as an endogenous control. ∆CT= (CT BRCA2 ∆17,18 – CT BRCA2 exon24). 7 T/T, 20 
T/C, and 11 C/T samples were analyzed in triplicated. Statistically significant differences betwen C/C and T/T 
genotypes were observed (BRCA2 ∆17,18 is upregulated in C/C carriers). Quantification in T/C carrirers  is 
compatible with a dosage effect. Overall, the data indicates that rs9534262 (c.7806-14T>C) modulates BRCA2 
alternative splicing. 
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Supp.  Figure S22. Minigene analysis of BRCA2 ∆18 and ∆17,18 expression level using BRCA2 full-lenght as an 
internal reference. Relative signal=(peak area splicing isoform/peak area full-lenght). BRCA2 ∆17,18 and BRCA2 ∆18  
are upregulated in rs9534262 C minigene.  
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Supp. Figure S23. A) Association between rs9534262 genotype and breast cancer risk. Allelic frequencies and two 
genetic models are tested. Healthy controls, sporadic breast cancer, and BRCAX (index cases from BRCAX families) 
cohorts are described in on-line method. B) Kaplan Meier analysis of the age at diagnosis (a dominant model is tested 
in the sporadic breast cancer cohort). The median age of diagnosis was 62 years for c.7806-14C carriers (CC+CT) 
and 54 years for non-carriers (TT), but differences were not statistically significant. C) Similar results were obtained 
when median age of diagnosis was compared between CC and TT genotypes (64 vs. 54 years). 
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Supp.  Table S1.  Analytical classification of in vitro splicing assays outputs. 
Class 2008 original IARC guide-lines1 2013 up-dated guide-lines2 
5 The variant allele produces major transcript(s) carrying a PTC, or in-
frame deletions disrupting known functional domain(s) 
The variant allele produces only transcript(s) carrying a PTC, or in-frame deletions 
disrupting known functional domain(s), determined by semi-quantitative or 
quantitative methods. 
4 The variant allele produces minor transcript(s) carrying a PTC, or in-
frame deletions disrupting known functional domain(s), at higher level 
than similar transcripts corresponding to physiological alternative 
splicing, or absent in wt controls.  
The variant allele produces aberrant transcript(s) carrying a PTC, or in-frame 
deletions disrupting known functional domain(s), these transcripts are not found in 
controls assayed in tandem, but further assessment to determine if the UV allele 
does or does not contribute to production of wildtype transcript. 
3 The variant allele produces major or minor transcript(s) carrying an in-
frame deletion not disrupting known functional domain(s), at a higher 
level than similar transcripts corresponding to physiological alternative 
splicing.  
All other transcript patterns e.g. the variant allele produces transcript(s) carrying 
an in-frame deletion not disrupting known functional domain(s), variant allele 
upregulates transcripts corresponding to physiological alternative splicing, at least 
some of which do not carry a PTC or are not an in-frame deletion disrupting 
known functional domains.   
2 The variant allele produces the same transcript(s) as the wildtype allele.  The variant allele produces transcript patterns comparable to that of wildtype 
controls assessed in tandem. 
                      1 
[Spurdle et al., 2008], 
2
 [Walker et al., 2013]  
In 2008, the IARC proposed a classification system aimed to achieve robustness in the analytical interpretation of in vitro splicing assays. The scheme has been up-dated 
recently. Somehow inevitably; these guide-lines introduce vague terms such as major, minor, or comparable (highlighted in bold italics by authors of the present report). Note 
that the 2008 original guide-lines describe splicing assay outputs, while the update is more concerned with methodological issues. By doing so, the meaning of the 
classification system has been slightly modified. For instance, analytical Class-4 does not reflect any more UV alleles expressing both wild-type and PTC transcripts, but a 
mere lack of analytical information (the UV contribution to wild-type expression has not been tested). Note that analytical guide-lines do not make a distinction between PTCs 
located 5’ or 3’ to the last 50 nucleotides of the penultimate exon, despite the fact that this might have clinical relevance.    
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Supp.  Table S2.  Primers used for Conventional RT-PCR Splicing Assays 
Name Sequence 
Forward primers 
E1 AGCTTACTCCGGCCAAAAA 
E2 GGATCCAAAGAGAGGCCAAC 
E4 GCAGATGATGTTTCCTGTCC 
E7 GGTCGTCAGACACCAAAACA 
E9 TGTGACAGACAGTGAAAAGAGAA 
E10.6 GCCTCTGAAAGTGGACTGGA 
E10.7 AAAAACACAGAAGGAATCGTCA 
E10 CTAATTAACTGTTCAGCCCAG 
E11.29 GCAGGCTTCACCTAAAAACG 
E11 CCAAGTCATGCCACACATTC 
E14 GAGACACTTGATTACTACAG 
E15 GAATGCCAGAGATATACAG 
E16.2 ATGGCGTTTCTAAACATTGC 
E19 CATCGCTTTTCAGTGATGGA 
E21 AGTTCGTGCTTTGCAAGATG 
E22 AATCATTTTGTTTAGTAAGGTC 
E25 AGGGCCACTTTCAAGAG 
Reverse primers (Fam-labeled) 
E3.1 ATTGGTACAGCGGCAGAGTC 
E4 GGACAGGAAACATCATCTGCT 
E8 ATCATGAGGAAAATACAGTTTCAGAT 
E10 TTCCAATGTGGTCTTTGC 
E10.3 TCTTTCTTTCTTTTGTTCTCTGTGTC 
E11 CAGAATTGTCCCAAAAGA 
E11.6 CGCAGGCTTGCTCAGTTTCTTT 
E11.7 TGTACTCTTCTGCAATATGT 
E12 GCCATCTGGAGTGCTTTTTG 
E13 AGTTGTGCGAAAGGGTAC 
E15 TTCGCATATCCTGTATATCTCTGG 
E16.1 ACCAAAATAATCTTCAGTGTGAAAC 
E17.1 CCATAGCTGCCAGTTTCCAT 
E19 GGGTCAGGAAAGAATCCAAG 
E22 TCATTCAACATTTGCCTGTGA 
E23 TTTTAGATTTTGAAGTTGCAAGA 
E24 CCGTGGCTGGTAAATCTGA 
E27 ATGCAAGTTCTTCGTCAGCT 
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Supp.Table S3. In silico analysis of splicing regulatory elements.  
 
 
 Splicing Enhancer Elements Splicing Silencer Elements 
Location HGVS description
1
 ESE Finder RESCUE-ESE PESE EIE Silencer motifs ESS Fas-ESS PESS IIE 
Exon 2 c.-39-26G>A - - - 2 new sites - - 2 sites broken - 1 new site 
Exon 5 c.426-89T>C 2 new sites 1 new / 1 broken - 4 sites broken - - - 1 site broken 2 sites broken 
Exon 6 c.516+14C>T 1 new site site broken 1 site broken 3 sites broken 1 site broken - - - 3 new sites 
Exon 7 c.631+25C>T - 3 sites broken - 4 sites broken 1 site broken - - 1 new site 2 new sites 
Exon 8 
c.680C>T (p.Ala227Val) 2 sites broken - 1 site broken - 1 new site - - - 2 new sites 
c.681+69C>T 2 sites broken - - - - - 2 new / 1 broken - 2 new sites 
Exon 9 c.682-2A>G - 3 sites broken 1 new site 3 sites broken 1 new site - - 2 sites broken - 
Exon 10 c.1773_1776 delTTAT (p.Ile591fs) - - - 3 new / 4 broken - - - 4 sites broken 4 sites broken 
Exon 11 
c.3264dupT ( p.Gln1089fs) 1 site broken 2 new sites new site 2 site broken 1 site broken - - - - 
c.6825G>A (p.Glu2275=) 1 site broken 1 new site 5 new sites 1 new site 1 site broken - - - - 
Exon 12 c.6928A>C (p.Thr2310Pro) 1 new/ 2 broken 1 site broken 1 new site 1 new site 1 new site - - - - 
Exon 14 c.7435+8A>G 1 new site - - 1 new/1 broken 1 new site - - - 2 new sites 
Exon 15 
c.7469T>C (p.Ile2490Thr) - - - 1 new site 1 site broken - - - - 
c.7617+1G>A 2 sites broken 2 new sites - 4 new sites 1 new site - 1 site broken 1 new site 1 site broken 
Exon 16 
c.7626G>A (p.Thr2542=) - site broken - - - - - 2 new sites 1 site broken 
c.7796A>G (p.Glu2599Gly) - - 2 sites broken 1 site broken 1 new site - - 1 site broken - 
c.7976+5G>T - - - 2 sites broken 2 sites broken - 1 site broken 1 site broken 2 new sites 
c.7976+57G>C 1 new site site broken - - 2 new / 1  broken - 2 sites broken - - 
Exon 18 
c.8010_8032del (p.Ala2671fs) 2 sites broken 6 sites broken 1 site broken 1new/14 broken 1 new/4 broken - 1 new site 1 site broken 2 sites broken 
c.8149G>T  (p.Ala2717Ser) new site 1 site broken 1 site broken 3 sites broken 2 sites broken - - - 1 new site 
Exon 20 
c.8524C>T ( p.Arg2842Cys) - - - - 1 site broken - - - 4 new sites 
c.8503T>C ( p.Ser2835Pro) 2 new sites site broken 1 new site 1 new /2 broken - - - - - 
c.8592C>T (p.Ala2864=) - - 1 new site 3 sites broken - - - - 2 new sites 
Exon 22 
c.8850G>T (p. Lys2950Asn) 1 new site site broken - 4 new / 1 broken 1 site broken - - 1 new site - 
c.8851G>A (p.Ala2951Thr) 1 new site 2 new sites 2 new sites 6 new sites 1 site broken - - - - 
Exon 23 
c.8954-5A>G 6 new sites 2 sites broken - 2 new sites 2 sites broken - - - - 
c.9004G>A (p.Asp3002Lys) 2 sites broken 3 sites broken 4 sites broken - 1 new/ 2 broken - - - - 
c.9026_9030del ( p.Tyr3009fs) 1 new site - - 2 sites broken 1 new/1 broken - - - 2 new/3 broken 
c.9038C>T (p.Thr3013Ile) 1 site broken 4 sites broken 1 site broken 2 sites broken 1 site broken - - - - 
Exon 27 c.9976A>T (p.Lys3326Ter) - - - 1 site broken - - - 2 new sites 3 new sites 
1 
Description according to HGVS guide-lines (http://www.hgvs.org/mutnomen). Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the GeneBank reference sequence NM_000059.3 
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Supp. Table S4. Haplotype analysis performed in 18 c.7617+1G>A carriers identified in 8 Spanish and 3 Danish families.  
   -0,45 Mb -0,28 Mb -0,18 Mb -64 kB -40 kB -23 Kb 0  +6 Kb +0,17Mb +0,28MB +1Mb +1,29 Mb +14Mb 
Origen FAMILY  ID ID D13S260 D13S1699 D13S1698 D13S1697 rs1799943 rs144848 c.7617+1 rs9534262 D13S1701 D13S1715 D13S1493 D13S267 D13153 
Spain 
 
HCSC_90 
1 159/169 145/149 166/178 218/218 G/G A/A G/A T/C 281/285 230/240 227/231 213/219 143/157 
2 159/161 145/149 158/178 218/218 G/G A/C G/A T/T 281/293 230/240 227/231 219/219 143/159 
3 159/161 145/149 158/178 218/218 G/G A/C G/A T/T 281/293 230/240 227/231 219/219 143/159 
 
HCSC_580 
 
4 159/163 149/149 158/178 218/218 A/G A/C G/A T/T 281/285 234/240 227/231 219/219 151/155 
5 159/163 149/149 158/178 218/218 A/G A/C G/A T/T 281/285 234/240 227/231 219/219 149/151 
6 159/165 145/149 162/178 218/218 G/G A/A G/A T/C 269/281 230/240 231/235 207/219 149/155 
HCSC_830 7 159/161 149/149 158/178 218/218 A/G A/C G/A T/C 281/293 240/244 231/235 207/219 152/155 
HPTH-55 10 159/159 145/149 172/178 218/218 A/G A/A G/A T/C 281/289 240/244 223/231 207/207 145/153 
Iov-99-09 
11 159/161 149/149 162/178 218/218 G/G A/C G/A T/T 281/289 240/244 223/231 219/219 151/157 
12 159/161 149/149 162/178 218/218 G/G A/C G/A T/T 281/289 240/244 223/231 219/219 147/157 
200 
13 159/161 149/149 164/178 218/222 A/G A/C G/A T/C 285/293 230/240 231/231 219/219 147/157 
14 159/161 145/149 166/178 211/218 G/G A/C G/A T/T 281/285 230/240 227/231 207/219 147/149 
1329 15 159/169 145/149 162/178 214/218 A/G A/C G/A T/C 281/293 234/240 223/235 207/213 157/161 
696 
16 159/165 145/149 174/178 218/222 G/G A/A G/A T/C 281/289 240/244 223/231 207/219 151/157 
17 159/151 145/149 176/178 218/218 G/G A/C G/A T/C 281/281 240/244 223/231 207/219 145/157 
Denmark 
 
D1 1 161/167 145/149 160/174 218/218 A/G A/A G/A T/C 289/293 244/244 227/227 207/207 151/157 
D2 2 167/167 145/149 160/166 218/218 G/G A/A G/A T/T 289/289 244/244 227/235 207/209 141/149 
D3 3 165/167 145/149 160/162 218/218 G/G A/A G/A T/T 289/297 244/244 223/235 207/221 153/163 
All eight families carrying this disease-causing mutation were resident in the Barcelona or Madrid metropolitan areas. We learnt through personal interviews 
that 7 families (we lack information on the remaining one) originated in the very same West-Spanish region (Extremadura). The length of the shared haplotype 
ranged from 0.51Mb to 1.74Mb. Interestingly, BRCA2 c.7617+1G>A has been reported previously as a Danish founder mutation highly prevalent in the Vejle 
area [Thomassen et al., 2011]. The authors used SNPs arrays to define a shared haplotype of 0.2Mb to 3.3Mb in 19 families carrying this mutation. For that 
reason, we have included in our analysis three Danish families carrying the BRCA2 c.7617+1G>A data. Our data (STR-based) is compatible with, but do not 
provide convincing evidence supporting a common origin for the Spanish and Danish mutations.  
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Supp.  Table S5. Haplotype analysis in 10 c.8954-5A>G carriers identified in 4 unrelated Spanish families 
All four families carrying this disease-causing mutation were residents in the Madrid or Valencia metropolitan areas. Personal interviews did not reveal any 
obvious common origin for these families. However, haplotype analysis identified a 1.28 Mb shared haplotype in all carriers, suggesting a founder effect 
(Supplemental Table 4). Families IVO_209 and IVO_305 have been reported previously [de Juan Jimenez et al., 2013]. BRCA2 c.8954-5A>G has been 
identified as well in three French families (http://www.umd.be/BRCA2/). 
 
 
 
 
 -0,45 Mb -1.1 Kb 0 +1 Mb +1.29 Mb +14 Mb 
Family ID ID D13S260 rs9534262 c.8954-5 D13S1493 D13S267 D13153 
 
HCSC_896 
 
1 168/168 T/C A/G 227/235 207/209 151/157 
Get483 
5 168/168 T/C A/G 227/243 207/209 157/161 
6 166/168 T/T A/G 227/243 207/207 151/157 
7 162/168 T/C A/G 227/235 207/209 145/157 
9 160/164 T/C A/G 227/235 207/219 141/149 
IVO_305 10 166/168 T/T A/G 223/227 207/213 157/159 
IVO_209 
13 160/166 T/C A/G 223/227 207/207 147/155 
15 160/160 T/T A/G 223/227 207/213 151/153 
17 160/166 T/C A/G 223/227 207/219 149/153 
19 160/166 T/C A/G 223/227 207/219 153/153 
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